Prostate News and Research

RSS

Miniature therapeutic ultrasound device

A prototype of a therapeutic ultrasound device, developed by a Cornell graduate student, fits in the palm of a hand, is battery-powered and packs enough punch to stabilize a gunshot wound or deliver drugs to brain cancer patients.

21 Dec 2008

Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon

Oncothyreon Inc. announced today that Merck KGaA of Darmstadt, Germany has licensed the right to manufacture Stimuvax and, through its affiliate EMD Serono Canada Inc., purchased current inventory and certain assets utilized for the manufacture of Stimuvax from Oncothyreon for consideration which includes net payments to Oncothyreon totaling approximately U.S. $13 million.

18 Dec 2008

Alfuzosin fails to reduce symptoms in chronic prostatitis

Alfuzosin, a drug commonly prescribed for men with chronic prostatitis, a painful disorder of the prostate and surrounding pelvic area, failed to significantly reduce symptoms in recently diagnosed men who had not been previously treated with this drug, according to a clinical trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH).

18 Dec 2008

Evaluation of treatments for benign prostatic enlargement

Research published by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme has found that transurethral resection, the most common operation for benign prostatic enlargement (BPE), remains a clinically and cost-effective treatment. BPE commonly causes older men to have difficulty passing urine and may require surgery to alleviate the problem.

18 Dec 2008

Prostate cancer discovered in 40% of men who test negative for the disease

Forty percent of men with prostate cancer may not even know they have it, according to a new research study by the Prostate Cancer Foundation of Chicago.

16 Dec 2008

Pre-existing diabetes for persons diagnosed with cancer associated with increased risk of death

Patients with diabetes at the time of a cancer diagnosis have an increased risk of death compared to patients without diabetes, according to a meta-analysis of studies reported in the December 17 issue of JAMA, the Journal of the American Medical Association.

16 Dec 2008

Low income men diagnosed more often with advanced prostate cancer

Coincident with the widespread adoption of PSA screening, the proportion of American men diagnosed with organ-confined, low risk prostate cancer has increased significantly during the last two decades. In a study scheduled for publication in the February 2009 issue of The Journal of Urology, researchers report that for low-income men, the opposite is true, with more men undiagnosed until their cancers had reached more advanced stages.

16 Dec 2008

USA's largest ever prostate cancer screening program shows high compliance and consistent results

Just under five per cent of the men who took part in the prostate cancer element of the USA's largest ever cancer screening trial were diagnosed with the disease and the majority of those were picked up by screening programmes, according to research published in the December issue of the urology journal BJU International .

15 Dec 2008

Discovery of promising new target in the battle against colorectal cancer

University of Texas Medical Branch at Galveston researchers have identified a promising new target in the battle against colorectal cancer - a biochemical pathway critical to the spread of tumors to new locations in the body.

15 Dec 2008

Gene subnetworks provide new prognostic markers for breast cancer

The metastasis or spread of breast cancer to other tissues in the body can be predicted more accurately by examining subnetworks of gene expression patterns in a patient's tumor, than by conventional gene expression microarrays, according to a presentation at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.

15 Dec 2008

Prostate cancer screening programme shows high compliance and consistent results in more than 38,000 men

15 Dec 2008

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

14 Dec 2008

New understanding on how the brain controls onset of puberty

A team of scientists from the University of Cambridge and the University of Cukurova in Turkey have taken a major step to understanding how the brain controls the onset of puberty.

12 Dec 2008

Researchers create tiny, implantable device that captures and kills cancer cells in the bloodstream

In a new tactic in the fight against cancer, Cornell University researcher Michael King has developed what he calls a lethal "lint brush" for the blood -- a tiny, implantable device that captures and kills cancer cells in the bloodstream before they spread through the body.

12 Dec 2008

AEterna Zentari completes recruitment for phase 3 trial with Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. has reported it has reached its goal of recruiting 500 patients for the safety study of the Phase 3 program in benign prostatic hyperplasia (BPH) with its flagship product candidate, cetrorelix, a novel investigational luteinizing hormone-releasing hormone (LHRH) antagonist.

11 Dec 2008

Neither vitamin E nor selenium reduce risk of prostate cancer

In perhaps the largest cancer chemoprevention trial ever conducted, researchers have found that supplementation with vitamin E or selenium, alone or in combination, was not associated with a lower risk of prostate cancer or other cancers.

10 Dec 2008

Vitamin C or E do not reduce prostate cancer, or other cancers risk

In a major cancer prevention study, long-term supplementation with vitamin E or C did not reduce the risk of prostate or other cancers for nearly 15,000 male physicians.

10 Dec 2008

Hormone therapy for prostate cancer does not appear to increase cardiac deaths

Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Massachusetts General Hospital (MGH) researchers.

10 Dec 2008

UK's first prostate cancer patient treated using RapidArc radiotherapy

65-year-old grandfather of six, Graham McCormack has become the first cancer patient in the UK to be treated using RapidArc radiotherapy technology from Varian Medical Systems.

10 Dec 2008

Married men more likely to be screened for prostate cancer

Although the link between early screening and prostate cancer survival is well established, men are less likely to go for early screening unless they have a wife or significant other living with them, according to a study published in Cancer Epidemiology, Biomarkers and Prevention , a journal of the American Association for Cancer Research.

8 Dec 2008